C-C Chemokine Receptor Type 4 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)- Pipeline Review, H2 2019’, provides in depth analysis on C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Ophthalmology and Respiratory under development targeting C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

– The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects

– The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Affitech A/S

ChemoCentryx Inc

Kyowa Kirin Co Ltd

RAPT Therapeutics Inc

Tizona Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development

Corion Biotech Srl

FLX Bio Inc

Kyowa Hakko Kirin Co Ltd

Tizona Therapeutics Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles

AT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBChMF-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-193 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mogamulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones

Featured News & Press Releases

Sep 27, 2018: FLX Bio announces first patient dosed with FLX475, a best-in-class CCR4 inhibitor for the treatment of multiple cancers

Sep 21, 2018: Kyowa Kirin announces Mogamulizumab received positive CHMP opinion for the treatment of Mycosis Fungoides and Sezary Syndrome

Aug 29, 2018: New therapy for rare lymphoma

Aug 21, 2018: Kyowa Hakko Kirin receives the partial change approval of POTELIGEO in Japan

Aug 13, 2018: Kyowa Kirin reports positive results from MAVORIC study

Aug 10, 2018: FDA approves Kyowa Kirin’s Poteligeo to treat two lymphoma types

Jun 04, 2018: Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO

May 30, 2018: Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Apr 12, 2018: FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting

Dec 11, 2017: Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

Nov 30, 2017: Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan

Nov 28, 2017: Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License Application

Oct 27, 2017: Kyowa Hakko Kirin Announces Marketing Authorization Application for Mogamulizumab Validated by European Medicines Agency

Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate

Aug 25, 2017: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sezary Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Affitech A/S, H2 2019

Pipeline by ChemoCentryx Inc, H2 2019

Pipeline by Kyowa Kirin Co Ltd, H2 2019

Pipeline by RAPT Therapeutics Inc, H2 2019

Pipeline by Tizona Therapeutics Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports